Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 15/20 | 0.47 |
| ▸ | BRAF | P15056 | 13/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342692 | 0.85 | KDR (0.57) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL4334102 | 0.84 | KDR (0.51) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL4342545 | 0.82 | KDR (0.50) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL4340643 | 0.82 | KDR (0.50) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL4335702 | 0.82 | KDR (0.49) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL13861127 | 0.81 | HRH3 (0.45) | KDRBRAFMAPK14FLT1 | |
| SCHEMBL4322864 | 0.81 | KDR (0.59) | KDRBRAFMAPK14RIPK2ABL1 | |
| SCHEMBL4322901 | 0.80 | MET (0.49) | KDRMAPK14RIPK2ABL1RET | |
| SCHEMBL12411764 | 0.80 | KDR (0.59) | KDRBRAFMAPK14RIPK2ERN1 | |
| SCHEMBL4322870 | 0.80 | KDR (0.45) | KDRBRAFMAPK14RIPK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | EPHX2 2388/4885P2RX3 662/4885KDR 7/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | EPHX2 2441/4885P2RX3 692/4885KDR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.